INTRODUCTION
Hepatitis B virus (HBV) is a non-cytopathic virus that causes liver disease of varying severity, ranging from acute self-limiting infection to chronic liver injury, which may lead to liver fibrosis, cirrhosis and hepatocellular carcinoma. Emerging evidence has suggested that cytokine-mediated immune responses play a pivotal role in determining the clinical outcome of HBV infection.
Interleukin-21 (IL-21) is a member of a large family of cytokines (IL-2, IL-4, IL-7, IL-9 and IL-15) whose receptors share a common receptor c chain (CD132). This cytokine is produced by activated CD4
1 T cells, in particular follicular T helper (Tfh) cells, Th17 cells and activated natural killer T cells. [1] [2] [3] [4] The effects of IL-21 are pleiotropic because of the broad cellular distribution of IL-21 receptor (IL-21R). 1, 5 A deepened understanding of the broadly immunomodulatory activity of IL-21 has attracted great interest in this cytokine in different disease settings, including chronic virus infections. In mouse models of chronic lymphocytic choriomeningitis virus infection, IL-21 produced by virus-specific CD4 1 T cells was essential for sustaining antiviral functions of CD8 1 T cells and preventing them from immune exhaustion. [6] [7] [8] Acutely-resolved hepatitis C virus was characterized by strong Th1/Th17 responses with specific expansion of IL-21-producing CD4 1 T cells and increased IL-21 levels in the plasma. 9 In patients with HIV-1 infection, reduced IL-21 production could be a contributing factor to the compromised cellular and humoral immune responses. 10, 11 Collectively, these studies indicate that IL-21may serve to limit viral persistence in chronic viral infection. Nevertheless, IL-21 could also trigger inflammatory pathways that promote tissue damage in various organs. 12, 13 Hence, it is possible that IL-21 exerts effects on inflammatory responses in the liver that promote the development of inflammatory disorders. Here, we review the current knowledge on the immunomodulatory effects of IL-21 in HBV infection.
FUNCTION OF IL-21 IN CELLULAR IMMUNE RESPONSES HBV-specific CD8
1 T cells play a crucial role in controlling HBV progression. Polyclonal and multispecific cytotoxic Tlymphocyte activity against HBV could be detected in patients with acute self-limiting HBV infection. 14, 15 However, in chronically infected individuals, HBV-specific CD8
1 T cells persist in a non-functional 'exhausted' state, characterized by an inability to produce important antiviral cytokines (e.g., IFN-c and TNFa), low cytotoxic activities and low proliferation in response to cognate antigen. 16 The exhaustion of specific cytotoxic CD8 10 These studies implicate the importance of CD4
1 T cells and IL-21 in promoting and sustaining immunity to chronic infections.
Depending on the age of an individual infected with human HBV, two different immune response patterns are observed. Infection during infancy often results in chronic persistence, while infection during adulthood usually leads to an acute response and viral clearance. The impact of age in the immune response to HBV infection resulting in viral clearance or persistence was explored in a transgenic mouse model of HBV infection. 21 Adult mice showed elevated HBV-specific IL-21 production in the liver, while young mice exhibited a paucity of IL-21-producing Tfh cells and fewer CD8
1 T cells in the liver. 21 Therefore, ineffective hepatic Tfh cell priming during early HBV infection can lead to decreased IL-21 production and hence, a reduced capacity to generate specific CD8 1 T-cell responses that are essential for viral clearance. Mechanistic studies have identified that IL-21 was required to mediate the clearance of HBV antigen in adult mice, indicating that IL-21 plays an important role in the age-dependent response to HBV clearance. Although HBV transgenic mice could not be considered as an ideal model of vertical infection due to the lack of a bona fide HBV infection, the system did reveal the potential involvement of increased IL-21 expression for the effective control of HBV replication; and this was confirmed in samples taken from patients with HBV infection. IL-21 expression was found to be elevated in acutely infected adults, but was low in patients with chronic HBV infection, even during active disease. 21 Cross-sectional data from our group showed that the inactive carrier (IC) patients, characterized by low or undetectable levels of HBV DNA, had higher serum IL-21 concentrations than patients in the immune tolerant stage. 22 Although IL-21 levels in chronic hepatitis B (CHB) and IC patients were comparable, there was a higher frequency of IL-21
CD4
1 T cells in the IC than the CHB group after either nonspecific (phorbol myristate acetate/ionomycin) or specific (HBV core antigen or peptides) stimulation. 22, 23 However, similar observations were not obtained in a recent study by Li et al. 24 This discrepancy may be attributed to patient selection, as viral load or viral antigens could influence the HBV-specific CD4
1 T-cell response in CHB patients. Interestingly, Li et al. found a significantly elevated frequency of HBcAg-specific IL-21
1

CD4
1 T cells in patients with acute hepatitis B (AHB). 24 This cell subset was negatively correlated with HBV DNA levels, but was positively correlated with HBc18-27-specific IFN-c-producing CD8 1 T cells in CHB patients. Moreover, HBcAg-specific CD4
1 T cells derived IL-21 from patients with AHB could enhance IFN-c and perforin expression by CD8 1 T cells from CHB patients. 24 These data indicated that HBcAg-specific IL-21-producing CD4
1 T-cell responses could promote the antiviral activity of CD8
1 T cells through IL-21 signaling. Notably, IL-21 in vitro could sustain the survival and function of HBc18-27-specific CD8
1 T cells in this study; while Ren et al. 25 reported that the addition of IL-21 in vitro could partially restore the function of HBV-specific CD8
1 T-cell responses in HBV/HIV-1-coinfected patients, but not in HBV-monoinfected patients. 25 Therefore, the precise effects of IL-21 on CD8
1 T-cell responses and the relevant mechanisms warrant further investigation.
FUNCTION OF IL-21 IN EFFECTIVE HUMORAL IMMUNITY
The appearance of antibodies against HBsAg and HBeAg indicate a favorable outcome of chronic HBV infection. The most critical site for the generation of T-dependent antibody responses is the germinal centers within lymphoid follicles in secondary lymphoid organs. A CD4 1 T-cell subset, named Tfh cells, resides primarily in B-cell follicles, and specializes in helping B cells develop into antibody-producing cells in germinal centers by secreting high levels of IL-21. 26, 27 In fact, accumulating evidence has supported the concept of the liver as a secondary lymphoid organ, which can support the priming of classical CD4
1 and CD8 1 T-cell responses. [28] [29] [30] [31] Although hepatic immune priming is generally considered to favor inherent tolerogenicity of the liver, [32] [33] [34] recent data from experimental animal models of human HBV have strongly demonstrated that age-dependent immune responses contributed to effective immune activation and antiviral immunity of the liver. 21, 35 Additionally, the hepatic lymphoid structures possessed the capacity to support the differentiation and maturation of B-cell responses, as well as the priming of Tfh cells. 35 Because of the elevated IL-21 expression from liver Tfh cells and the increased numbers of IgG-expressing B cells, adult recipient mice could generate an effective humoral immune response that resulted in life-long clearance of HBsAg. 21 However, in the absence of IL-21R on donor splenocytes, adult mice were unable to produce HBsAb, leading to HBV antigen persistence. 21 Despite being phenotypically Tfh-like, IL-21R knockout CD4
1 T cells were functionally devoid of B helper cell activity. 36 Therefore, IL-21R knockout mice with lymphocytic choriomeningitis virus infection exhibited a profound defect in the generation of long-lived plasma cells and in the maintenance of antiviral antibody response over time, highlighting the importance of IL-21 in humoral immunity to viral infection. 36 Using a longitudinal cohort under telbivudine treatment, our group found that HBeAg seroconversion during antiviral therapy for HBeAg positive patients with CHB was associated with high serum IL-21 concentrations at the week 12 time point: a strong predictor independent of other common parameters, such as HBV DNA and ALT levels. 22 The data suggested that serum IL-21 levels may be identified as an immune biomarker for HBeAg seroconversion. 37 However, in HIV/HBVcoinfected patients placed under HBV-active combination antiretroviral therapy, there was little evidence to support the association between IL-21 and HBeAg seroconversion. 38 HBeAg loss was associated with enhanced CD4
1 T cells responses to HBV in adefovir dipivoxil-treated HBeAg-positive patients with CHB. 39 In a cross-sectional study, the IC patients characterized by the presence of anti-HBe showed an increased frequency of HBV-specific IL-21
1
CD4
1 T cells. 22 Thus, the source of IL-21 in patients who achieved HBeAg seroconversion was likely derived from HBV-specific CD4 1 T cells, especially Tfh cells, which are the predominant producers of IL-21. Recently, the importance of Tfh cells at other sites has become evident. 26 Several studies have demonstrated that CXCR5 1
1 T cells in the peripheral circulation shared some properties with Tfh cells. [40] [41] [42] Moreover, CXCR5
1
CD4
1 T cells derived from both the circulation and germinal centers potently induced antibody production in in vitro cocultures with autologous B cells. 42, 43 Thus, circulating CXCR5
1
CD4
1 T cells, which are easily accessible in the peripheral blood, may serve as surrogates for assessing the function of Tfh cells. This concept was further supported by our observation that circulating CXCR5
1
CD4
1 T cells were closely related to Tfh cells of the lymphoid organs in patients with chronic HBV infection. 23 Peripheral blood CXCR5
1
CD4
1 T cells also participate in HBV-related immune responses. In a study by Feng et al., 44 immune active CHB patients had increased frequencies of peripheral blood CXCR5
1
CD4
1 T cells. Consistent with this observation, we recently found that both the overall and HBV-specific circulating CXCR5
1
CD4
1 T cells were expanded in chronic HBV infection, and a high frequency of this cell subset was associated with HBeAg seroconversion in both cross-sectional and longitudinal studies. 23 More importantly, the CXCR5 1 CD4 1 T cells from HBeAg seroconverters could promote anti-HBe production by autologous B cells in vitro in an IL-21-dependent manner. 23 These data support the notion that IL-21 represents a major mediator for the function of CXCR5
1
CD4
1 T cells in the induction and maintenance of HBeAg seroconversion.
FUNCTION OF IL-21 IN LIVER INJURY AND DISEASE PROGRESSION In addition to Tfh cells, IL-17-producing-CD4
1 T cells (Th17) also secrete IL-21. Meanwhile, retinoic acid receptor-related orphan receptor gamma t, a transcription factor induced by IL-21, is essential for Th17 development; 45 this autocrine property can also support high levels of persistent (and perhaps detrimental) Th17 cells. The highly increased frequency of Th17 cells in peripheral blood mononuclear cell has been observed in CHB patients with severe liver damage, 46 strongly supporting the hypothesis that Th17-related cytokines, such as IL-21, maybe involved in the pathogenesis of hepatitis B and promote HBV infection-related liver injury.
In patients with hepatitis B-related acute-on-chronic liver failure, the serum levels of IL-21 and the frequencies of IL-21-producing-CD4
1 T cells were significantly elevated, and both of these factors declined with clinical improvement in surviving subjects. 47 Moreover, a high level of serum IL-21 was identified to be positively associated with increased model for end-stage liver disease score and mortality. In vitro, IL-21 could upregulate the expression of the pro-inflammatory cytokines IL-1b, IL-6 and TNF-a in peripheral blood mononuclear cell from both healthy subjects and CHB patients. 47 These results suggest that IL-21may have a causal role in the development of severe liver inflammation. However, there was no correlation between serum IL-21 and ALT levels in this study, which is in agreement with our subsequent finding from immune activated CHB patients; 22 therefore, IL-21 production may be related to the immune response to HBV, rather than to the degree of liver inflammation. In contrast, a recent study from Pan et al. 48 found that IL-21 expression in serum and liver tissues were positively correlated with serum ALT and AST levels in CHB. Meanwhile, the intensity of IL-21 staining in liver tissues was associated with the grade of liver damage; this observation was consistent with a previous report showing that Th17 cells were largely accumulated in the liver of CHB patients and correlated positively with the histological activity index. 46 These findings support the potentiality that serum IL-21 levels may serve as a biomarker for evaluating the severity of hepatic inflammation as well as liver injury in CHB. Taken together, collective evidence provided by current studies suggest that aberrant IL-21 responses may be associated with the liver injury during the pathogenesis of chronic HBV infection.
Chronic inflammation and liver injury initiated by HBV infection have been considered major factors leading to liver fibrosis. The host immune response is pivotal for fibrogenesis in liver cirrhosis. Increased peripheral and intrahepatic Th17 cells have been detected in patients with HBV-associated liver cirrhosis (HBV-LC) and have been found to contribute to the severity of disease progression through induction of hepatic stellate cell activation, 49 raising the possibility that IL-21 may be involved in the process of liver fibrogenesis. Indeed, studies in animal models have demonstrated that IL-21 could act as a vital profibrogenic factor in vivo by promoting fibrosis through facilitating the development of CD4 1 T helper 2 responses. 50 In patients with HBV-LC, increased peripheral numbers of IL-21 1 CD4 1 T cells and elevated plasma levels of IL-21 were observed. Meanwhile, consistent with the findings from CHB, liver IL-21
1 cells were positively correlated with fibrotic staging scores, and clinical progression from CHB to LC. 51 Mechanisms underlying this process were attributed to IL-21, which could promote activation, inhibit apoptosis and enhance collagen production, without affecting the proliferation of hepatic stellate cell. 51 These observations indicated that IL-21 may participate in the fibrogenesis of liver cirrhosis. Therefore, therapeutic strategies targeting the neutralization of IL-21 might be a viable treatment for liver cirrhosis.
CONCLUSIONS AND FUTURE PERSPECTIVES
IL-21 is an important cytokine that regulates both cellular and humoral immune responses. In this review, we highlighted some properties of IL-21 in the context of HBV infection in murine models and humans. As a critical helper factor, IL-21 improves the functional quality of the antiviral CD8
1 T cells response that is required for viral control. High levels of serum IL-21 after antiviral therapy correlate with the development of HBV-specific antibody responses. Therefore, IL-21 derived from CD4 1 T cells acts as an effective intermediary for the optimal generation of specific CD8
1 T and B-cell responses that are crucial for viral clearance and disease outcome, indicating a beneficial role of increasing IL-21 levels in HBV infection. However, elevated IL-21 expression may also aggravate the development of HBV-induced liver cirrhosis and the severity of liver injury. Taken together, IL-21 exerts a diverse range of effects at different stages of HBV infection (Figure 1) .
While current findings have improved our understanding regarding the immunomodulatory effects of IL-21 in HBV infection, many unresolved issues still remain. For example, it is necessary to dissect how IL-21 interacts with other components of the immune system, due to the pleiotropic effects of this cytokine. Additionally, it is unknown whether the predictive value of IL-21 is specific to telbivudine treatment in CHB patients. Since patients with IFN-a treatment have relatively higher rates of HBeAg seroconversion, it will be interesting to investigate whether the Tfh/IL-21/B cells axis plays an important 1 T cells by enhancing IFN-c, perforin and granzyme expression, eventually leading to viral control. 21,24,25 (b) In combination with costimulatory signals, IL-21 secreted by Tfh cells regulates B-cell proliferation and differentiation into antibody-secreting plasma cells, thus facilitating the production of HBV-specific antibodies. 21, 23 (c) Aberrant IL-21 derived from Th17 cells (perhaps Tfh cells) can upregulate the expression of the pro-inflammatory cytokines IL-1b, IL-6 and TNF-a in PBMC from CHB patients, resulting in immune-mediated liver injury and inflammation. [46] [47] [48] (d) IL-21 contributes to the severity of disease progression through HSC activation, and might be involved in the process of liver fibrogenesis. [49] [50] [51] Currently, little information is known regarding the immune effects of IL-21 on NK or NKT cells in the context of HBV infection. APC, antigen-presenting cell; COL IV, collagen type IV; HA, hyaluronic acid; HSC, hepatic stellate cell; LN, laminin; PBMC, peripheral blood mononuclear cell; PIIINP, procollagen type III N-terminal peptide; Tfh, follicular T helper; TNF-a, tumor necrosis factor-alpha. role in determining this outcome, and to uncover the relevant immune and molecular mechanisms underlying this process. Furthermore, that IL-21 is over-expressed in HBV-LC raised a question meriting attention to the role of IL-21 in HBV-related hepatocellular carcinoma. Future work is needed to elucidate whether IL-21 can function as a suppressive or stimulatory factor in the development of HBV-related HCC, while this has yet to be explored, it will definitely provide insights to the development of new therapeutic interventions for this malignant cancer.
Although the precise role of IL-21 during HBV infection needs to be explored in depth, recent findings from animal models and clinical cohorts have provided a promising prospect for the application of an IL-21-based immunotherapy approach in the treatment of chronic HBV infection. However, it is conceivable that manipulating the effects of IL-21 may be a double-edged sword. In this context, the targeting of IL-21 in vivo to optimize therapeutic efficacy will be a future challenge in this field.
